Q&A Genmab 2021-05-17

	17/5 15:01 af Jan Van de Winkel	In January, Janssen's DARZALEX FASPRO became the first and only FDA-approved treatment for AL amyloidosis..
	17/5 15:01 af Jan Van de Winkel	During the first quarter of 2021, there were significant events for both DARZALEX and Kesimpta..
	17/5 15:00 af Jan Van de Winkel	Recent highlights include the US FDA's acceptance of the tisotumab vedotin BLA for priority review based on the innovaTV 204 Phase II study. If approved, tisotumab vedotin would be a first-in-class therapy, and we believe that it has the potential to become an important treatment option for patients with recurrent or metastatic cervical cancer. The PDUFA target date for a potential U.S. FDA approval is October of this year..
	17/5 15:00 af Helge Larsen/PI-redaktør	Can you give us a short-term update on the financial highlights and the key achievements in Q1?
	17/5 14:59 af Jan Van de Winkel	Thank you for having us back to discuss Genmab’s results for Q1 2021. We look forward to yet another inspiring session with clever questions and energizing interaction as always.
	17/5 14:59 af Helge Larsen/PI-redaktør	Good afternoon Jan van de Winkel. Welcome to Q&A here on ProInvestor.com. We are very happy to have you back here and ready to answer questions from our investors.
	17/5 14:59 af Jan Van de Winkel	Yes,we are here and ready
	17/5 14:58 af Helge Larsen/PI-redaktør	Hi Jan van de Winkel. Are you online?
	17/5 06:56 af Helge Larsen/PI-redaktør	Denne Q&A starter kl. 15.